These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12702887)

  • 1. [Comparative in vitro bacteriostatic and bactericidal activity of levofloxacin and ciprofloxacin against urinary tract pathogens determined by MIC, MBC, Time-Kill curves and bactericidal index analysis].
    Noviello S; Ianniello F; Leone S; Esposito S
    Infez Med; 2002 Jun; 10(2):100-6. PubMed ID: 12702887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of levofloxacin and ciprofloxacin against urinary pathogens.
    Drago L; De Vecchi E; Mombelli B; Nicola L; Valli M; Gismondo MR
    J Antimicrob Chemother; 2001 Jul; 48(1):37-45. PubMed ID: 11418511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
    Visalli MA; Jacobs MR; Appelbaum PC
    Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bactericidal activity of levofloxacin and ciprofloxacin on clinical isolates of different phenotypes of Pseudomonas aeruginosa.
    Segatore B; Setacci D; Perilli M; Franceschini N; Marchetti F; Amicosante G
    Int J Antimicrob Agents; 2000 Jan; 13(3):223-6. PubMed ID: 10724029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of 4-quinolones against Pseudomonas aeruginosa.
    Morissey I; Smith JT
    Arzneimittelforschung; 1994 Oct; 44(10):1157-61. PubMed ID: 7818593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bactericidal activity of levofloxacin against ampicillin-resistant and ampicillin-susceptible Haemophilus influenzae in comparison with ofloxacin, ciprofloxacin and sparfloxacin.
    Dabernat H
    Int J Antimicrob Agents; 1999 Feb; 11(2):139-43. PubMed ID: 10221417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
    Gómez-Lus R; Adrián F; del Campo R; Gómez-Lus P; Sánchez S; García C; Rubio MC
    Int J Antimicrob Agents; 2001 Jul; 18(1):49-54. PubMed ID: 11463526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of difloxacin against canine bacterial isolates.
    van den Hoven R; Wagenaar JA; Walker RD
    J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.
    MacGowan AP; Wootton M; Holt HA
    J Antimicrob Chemother; 1999 Mar; 43(3):345-9. PubMed ID: 10223589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
    Mather R; Karenchak LM; Romanowski EG; Kowalski RP
    Am J Ophthalmol; 2002 Apr; 133(4):463-6. PubMed ID: 11931779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.
    Wagenlehner FM; Kinzig-Schippers M; Sörgel F; Weidner W; Naber KG
    Int J Antimicrob Agents; 2006 Dec; 28(6):551-9. PubMed ID: 17101261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
    Noviello S; Ianniello F; Leone S; Esposito S
    Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency of quorum sensing system inhibits the resistance selection of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin in vitro.
    Gao Y; Duan J; Geng X; Zhang Z; Zhang R; Li X; Wang S; Kang J; Yin D; Song Y
    J Glob Antimicrob Resist; 2017 Sep; 10():113-119. PubMed ID: 28729210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of the bacteriostatic and bactericidal activity of levofloxacin against Pasteurella strains isolated from man].
    Heurtin C; Desbordes L; Travert MF; Donnio PY; Avril JL
    Pathol Biol (Paris); 2001 Oct; 49(8):606-11. PubMed ID: 11692747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
    Madaras-Kelly KJ; Demasters TA
    Diagn Microbiol Infect Dis; 2000 Aug; 37(4):253-60. PubMed ID: 10974576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gepotidacin (GSK2140944)
    Flamm RK; Farrell DJ; Rhomberg PR; Scangarella-Oman NE; Sader HS
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.